484 related articles for article (PubMed ID: 27111033)
1. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.
Kim J; Mouw KW; Polak P; Braunstein LZ; Kamburov A; Kwiatkowski DJ; Rosenberg JE; Van Allen EM; D'Andrea A; Getz G
Nat Genet; 2016 Jun; 48(6):600-606. PubMed ID: 27111033
[TBL] [Abstract][Full Text] [Related]
2.
Li Q; Damish AW; Frazier Z; Liu D; Reznichenko E; Kamburov A; Bell A; Zhao H; Jordan EJ; Gao SP; Ma J; Abbosh PH; Bellmunt J; Plimack ER; Lazaro JB; Solit DB; Bajorin D; Rosenberg JE; D'Andrea AD; Riaz N; Van Allen EM; Iyer G; Mouw KW
Clin Cancer Res; 2019 Feb; 25(3):977-988. PubMed ID: 29980530
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer.
Börcsök J; Sztupinszki Z; Bekele R; Gao SP; Diossy M; Samant AS; Dillon KM; Tisza V; Spisák S; Rusz O; Csabai I; Pappot H; Frazier ZJ; Konieczkowski DJ; Liu D; Vasani N; Rodrigues JA; Solit DB; Hoffman-Censits JH; Plimack ER; Rosenberg JE; Lazaro JB; Taplin ME; Iyer G; Brunak S; Lozsa R; Van Allen EM; Szüts D; Mouw KW; Szallasi Z
Clin Cancer Res; 2021 Apr; 27(7):2011-2022. PubMed ID: 33208343
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
[TBL] [Abstract][Full Text] [Related]
5. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.
Van Allen EM; Mouw KW; Kim P; Iyer G; Wagle N; Al-Ahmadie H; Zhu C; Ostrovnaya I; Kryukov GV; O'Connor KW; Sfakianos J; Garcia-Grossman I; Kim J; Guancial EA; Bambury R; Bahl S; Gupta N; Farlow D; Qu A; Signoretti S; Barletta JA; Reuter V; Boehm J; Lawrence M; Getz G; Kantoff P; Bochner BH; Choueiri TK; Bajorin DF; Solit DB; Gabriel S; D'Andrea A; Garraway LA; Rosenberg JE
Cancer Discov; 2014 Oct; 4(10):1140-53. PubMed ID: 25096233
[TBL] [Abstract][Full Text] [Related]
6. Genomic characterization of response to chemoradiation in urothelial bladder cancer.
Desai NB; Scott SN; Zabor EC; Cha EK; Hreiki J; Sfakianos JP; Ramirez R; Bagrodia A; Rosenberg JE; Bajorin DF; Berger MF; Bochner BH; Zelefsky MJ; Kollmeier MA; Ostrovnaya I; Al-Ahmadie HA; Solit DB; Iyer G
Cancer; 2016 Dec; 122(23):3715-3723. PubMed ID: 27479538
[TBL] [Abstract][Full Text] [Related]
7. Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
Bellmunt J; Kim J; Reardon B; Perera-Bel J; Orsola A; Rodriguez-Vida A; Wankowicz SA; Bowden M; Barletta JA; Morote J; de Torres I; Juanpere N; Lloreta-Trull J; Hernandez S; Mouw KW; Taplin ME; Cejas P; Long HW; Van Allen EM; Getz G; Kwiatkowski DJ
Cancer Res; 2020 Oct; 80(20):4476-4486. PubMed ID: 32868381
[TBL] [Abstract][Full Text] [Related]
8. Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.
Prosz A; Duan H; Tisza V; Sahgal P; Topka S; Klus GT; Börcsök J; Sztupinszki Z; Hanlon T; Diossy M; Vizkeleti L; Stormoen DR; Csabai I; Pappot H; Vijai J; Offit K; Ried T; Sethi N; Mouw KW; Spisak S; Pathania S; Szallasi Z
Sci Rep; 2023 Nov; 13(1):20567. PubMed ID: 37996508
[TBL] [Abstract][Full Text] [Related]
9. Expansion of the clinical and molecular spectrum of an XPD-related disorder linked to biallelic mutations in ERCC2 gene.
Agolini E; Botta E; Lodi M; Digilio MC; Rinelli M; Bellacchio E; Alesi V; Nardo T; Zambruno G; Orioli D; Alessi I; Boccuto L; Rossi S; Carai A; Colafati GS; Cacchione A; Dallapiccola B; Novelli A; Mastronuzzi A
Clin Genet; 2021 Jun; 99(6):842-848. PubMed ID: 33733458
[TBL] [Abstract][Full Text] [Related]
10. Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India.
Gangawar R; Ahirwar D; Mandhani A; Mittal RD
Med Oncol; 2010 Jun; 27(2):159-66. PubMed ID: 19242824
[TBL] [Abstract][Full Text] [Related]
11. Complex association between ERCC2 gene polymorphisms, gender, smoking and the susceptibility to bladder cancer: a meta-analysis.
Wu Y; Yang Y
Tumour Biol; 2014 Jun; 35(6):5245-57. PubMed ID: 24504678
[TBL] [Abstract][Full Text] [Related]
12. The mutational impact of Illudin S on human cells.
Casimir L; Zimmer S; Racine-Brassard F; Jacques PÉ; Maréchal A
DNA Repair (Amst); 2023 Feb; 122():103433. PubMed ID: 36566616
[TBL] [Abstract][Full Text] [Related]
13. Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.
Gerald T; Margulis V; Meng X; Bagrodia A; Cole S; Qin Q; Call SG; Mauer E; Lotan Y; Woldu SL
Urol Oncol; 2023 Mar; 41(3):148.e17-148.e24. PubMed ID: 36653279
[TBL] [Abstract][Full Text] [Related]
14. DNA Damage Response Gene Alterations in Urothelial Cancer: Ready for Practice?
Grivas P
Clin Cancer Res; 2019 Feb; 25(3):907-909. PubMed ID: 30455203
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in XRCC1, ERCC2, and ERCC3 DNA repair genes, CYP1A1 xenobiotic metabolism gene, and tobacco are associated with bladder cancer susceptibility in Tunisian population.
Feki-Tounsi M; Khlifi R; Louati I; Fourati M; Mhiri MN; Hamza-Chaffai A; Rebai A
Environ Sci Pollut Res Int; 2017 Oct; 24(28):22476-22484. PubMed ID: 28803404
[TBL] [Abstract][Full Text] [Related]
16. ERCC2/XPD Lys751Gln alter DNA repair efficiency of platinum-induced DNA damage through P53 pathway.
Zhang G; Guan Y; Zhao Y; van der Straaten T; Xiao S; Xue P; Zhu G; Liu Q; Cai Y; Jin C; Yang J; Wu S; Lu X
Chem Biol Interact; 2017 Feb; 263():55-65. PubMed ID: 28027876
[TBL] [Abstract][Full Text] [Related]
17. Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer.
Topka S; Steinsnyder Z; Ravichandran V; Tkachuk K; Kemel Y; Bandlamudi C; Winkel Madsen M; Furberg H; Ouerfelli O; Rudin CM; Iyer G; Lipkin SM; Mukherjee S; Solit DB; Berger MF; Bajorin DF; Rosenberg JE; Taylor BS; de Stanchina E; Vijai J; Offit K
Clin Cancer Res; 2021 Apr; 27(7):1997-2010. PubMed ID: 33199492
[TBL] [Abstract][Full Text] [Related]
18. DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort.
Fontana L; Bosviel R; Delort L; Guy L; Chalabi N; Kwiatkowski F; Satih S; Rabiau N; Boiteux JP; Chamoux A; Bignon YJ; Bernard-Gallon DJ
Anticancer Res; 2008; 28(3B):1853-6. PubMed ID: 18630471
[TBL] [Abstract][Full Text] [Related]
19. Frequent retrotransposition of endogenous genes in ERCC2-deficient cells derived from a patient with xeroderma pigmentosum.
Aoto S; Katagiri S; Wang Y; Pagnamenta AT; Sakamoto-Abutani R; Toyoda M; Umezawa A; Okamura K
Stem Cell Res Ther; 2019 Aug; 10(1):273. PubMed ID: 31455402
[TBL] [Abstract][Full Text] [Related]
20. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
